APPROVED FOR THE TREATMENT OF IPF AND SSc-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Recent developments in the management of ILD - Dr Felix Chua (Royal Brompton Hospital)
Document ID: EM-ASK-100049
25/04/2023
Author: Boehringer Ingelheim
RELATED CONTENT
EM-ASK-100049
Production Date: April 2023
Production Date: April 2023
